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Purpose: High-dose benzodiazepines (BZDs) abuse has been documented to cause
multidomain cognitive dysfunction. We explored whether cognitive abnormalities to
high-dose BZD abuse might be reversed by detoxification with slow subcutaneous
infusion of flumazenil.
Methods: We recruited 96 patients consecutively admitted to the Department
of Internal Medicine, Addiction Medicine Unit, Verona University Hospital, Italy for
detoxification from high-dose BZD dependence. After selection for inclusion and
exclusion criteria, 50 patients (23 men, 27 women; age 42.7 ± 10.3 years) were
included. They underwent a comprehensive neuropsychological battery to explore
verbal memory, visuospatial memory, working memory, attention, and executive
functions 28–30 days prior to admission for detoxification (T0) and at the end of
detoxification, i.e., 7 days after admission (T1). A group of 50 healthy adults (24
men, 26 women; mean age 44.5 ± 12.8 years) matched for age, sex, and education
served as controls.
Results: At T0, patients scored significantly worse than healthy controls in all the
neuropsychological tests. Depression and anxiety scores were associated with impaired
verbal memory at T0 in patients. T1–T0 comparison showed improved performances in
all neuropsychological tests after the end of detoxification in patients.
Conclusion: We confirmed that all neuropsychological domains were significantly
and profoundly impaired by high-dose BZD abuse and documented that
cognitive abnormalities improved after detoxification with slow subcutaneous
infusion of flumazenil.
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INTRODUCTION
Benzodiazepines (BZDs) and related Z-drugs (Zs) are gamma-amino-butyric acid type A
(GABA-A) positive allosteric modulators, which are prescribed for anxiety and insomnia and
represent one of the most widely used groups of pharmaceuticals worldwide (Soyka, 2017). Among
patients on BZDs or Zs, 6–76% become long-term users, 15–44% experience moderate-to-severe
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withdrawal symptoms and 3–4% show misuse or dependence
(Faccini et al., 2016).
High-dose BZD dependence is a specific substance use
disorder (Tamburin et al., 2017a) associated with reduced quality
of life (Lugoboni et al., 2014; Tamburin et al., 2017b) and difficult
treatment (Stevens et al., 2014; Liebrenz et al., 2015). A cross-
sectional telephone survey carried out in France, Germany,
Italy and the United Kingdom estimated that 0.14 and 0.06%
of the general population took higher-than-recommended dose
of anxiolytics and hypnotics, respectively (Ohayon and Lader,
2002). These data are in accordance with the estimated prevalence
of 0.16% of high-dose BZD users in Switzerland (Petitjean et al.,
2007) and suggest the number of high-dose BZD/Z abusers to be
around 1.5 million in Europe and 600,000 in the United States.
Long-term BZD use was reported to be associated with
abnormalities in cognitive functions, including attention,
memory and learning (Boeuf-Cazou et al., 2011; Barker et al.,
2004a; Puustinen et al., 2014; Helmes and Østbye, 2015; Fond
et al., 2018), and higher risk of delirium, cognitive decline, falls,
fractures, injuries, and road accidents (Finkle et al., 2011; van
der Sluiszen et al., 2017; Kok et al., 2018; Picton et al., 2018;
Wedmann et al., 2019). However, most of these reports were
from people at higher risk of cognitive decline, such as elderly
people (Finkle et al., 2011; Helmes and Østbye, 2015; Picton
et al., 2018), intensive care unit patients (Kok et al., 2018),
or patients with schizophrenia (Fond et al., 2018), whereby
separating side effects of BZDs from symptoms of aging or
a pathological state may be troublesome. Furthermore, BZD
use was suggested to increase the risk of dementia, but studies
reported contrasting data on this point, possibly because the
presence of sleep disorders or neuropsychiatric symptoms in
patients with preclinical dementia may lead to an increased
probability of being prescribed a BZD (Gray et al., 2016; Islam
et al., 2016; Zhang et al., 2016). Neuroimaging reports yielded
conflicting findings, also, in that BZD use was reported to be
associated either with brain volume reduction in schizophrenia
(Huhtaniska et al., 2017), or lower cortical β-amyloid levels in
non-demented elderly people (Chung et al., 2016).
High-dose BZD users offer a unique chance to explore the
effect of BZD/Z on cognition, because of their relatively young
age, and the absence of significant comorbidity in many of them
(Federico et al., 2017). We have previously shown profound
multidomain dysfunction involving all cognitive domains in
a group of young adults (age 44.2 ± 9.7) with high-dose
BZD/Z abuse, no neurological or psychiatric comorbidity, except
depression and anxiety disorders, and no concurrent substance
use disorders (Federico et al., 2017).
Different treatments have been proposed for BZD
detoxification (Kawasaki et al., 2012; Soyka, 2017). Low-dose
slow subcutaneous infusion of flumazenil, a GABA-A negative
allosteric modulator, has been proposed for the detoxification
from BZD dependence (Hood et al., 2014; Soyka, 2017), and
is currently given to patients with high-dose BZD/Z abuse to
achieve rapid detoxification (Faccini et al., 2016; Tamburin et al.,
2017a). Human data on the cognitive effects of flumazenil are
lacking, but the chronic administration of flumazenil may have
a protective role against cognitive decline in rats (Colas et al.,
2017). In addition, the short-term administration of flumazenil
was reported to improve long-term memory in a mouse model
of Down’s syndrome (Marczynski et al., 1994).
The present study is aimed to explore whether cognitive
changes to high-dose BZD abuse might be reversed by
detoxification with flumazenil slow subcutaneous infusion
(Faccini et al., 2016; Tamburin et al., 2017a). To achieve this
aim, we assessed a group of high-dose BZD abusers who
underwent a thorough neuropsychological testing before and
after flumazenil slow infusion.
MATERIALS AND METHODS
Patients and Controls
From January to December 2017, we recruited 96 patients
consecutively admitted to the Department of Internal Medicine,
Addiction Medicine Unit, Verona University Hospital, Italy
for detoxification from high-dose BZD dependence, defined as
BZD dependence according to DSM-IV-TR criteria (American
Psychiatric Association [APA], 2000), with abuse lasting more
than 6 months, daily BDZ intake exceeding at least five times the
maximum daily recommended dose (i.e., >50 mg diazepam/day)
(Faccini et al., 2016), and problematic use, such as mixing
BZDs, escalating dosage, using BZDs for recreational purposes,
or obtaining BZDs illegally (Lugoboni et al., 2014; Liebrenz et al.,
2015; Tamburin et al., 2017a).
The BZD/Z dose was standardized as daily diazepam dose
equivalent (DDDE, mg) according to conversion tables (Faccini
et al., 2016; Tamburin et al., 2017a).
The inclusion criteria were: (a) age ≥18 years, (b) formal
education ≥ 8 years, (c) Italian as mother language, (d) normal or
corrected-to-normal vision, (e) no hearing loss, (f) no acute drug
intoxication, (g) no neurological diseases that might interfere
with cognition, (h) normal overall cognition documented by a
Mini Mental State Examination score >24/30, (i) no psychiatric
diseases except depression and/or anxiety disorders, and (j) no
documented concurrent alcohol or other substance use disorder
(Federico et al., 2017).
After selection, 50 patients (23 men, 27 women; age
42.7 ± 10.3 years, median 42; education 12.8 ± 4.9 years, median
13) were included (Figure 1). A group of 50 age, sex, and
education-matched healthy subjects not assuming BZDs served
as controls (24 men, 26 women; age 44.5 ± 12.8 years, median 44;
education 13.1 ± 3.4 years, median 13; n.s. for all comparisons vs.
patients). Baseline demographic variables in patients and controls
are shown in Table 1.
The study was conducted according to the Declaration of
Helsinki and approved by the ethics committee of the Verona
University Hospital (approval code 683CESC). Patients and
controls gave written informed consent to the study and to
off-label administration of flumazenil (patients only).
Neuropsychological Assessment
Patients and controls underwent a comprehensive
neuropsychological battery to explore verbal, visuospatial and
working memory, attention, and executive functions (Federico
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FIGURE 1 | Flow diagram of the study and reasons for patients’ exclusion.
TABLE 1 | Baseline demographic variables in patients and controls.
Patients Controls p value
Agea 42.7±10.3 44.5±12.8 n.s.
Sex (M/F) 23/27 24/26 n.s.
Educationa 12.8±4.9 13.1±3.4 n.s.
Smoke (yes/no) 27/23 24/26 n.s.
Alcohol (yes/no) 2/48 0/50 n.s.
aData reported as mean ± S.D.
et al., 2017; Cecchini et al., 2019). Neuropsychological assessment
was performed at T0 (i.e., 28–30 days prior to admission for
detoxification) and T1 (i.e., at the end of detoxification, 7 days
after admission). BDZs could be taken more than 8 h prior to
the T0 neuropsychological assessment, which was performed
28–30 days before the detoxification treatment. The BZD
of abuse was stopped 7 days before T1 neuropsychological
assessment. From the first day of detoxification, patients received
oral clonazepam in the morning (around 8 a.m.) at progressively
decreasing dosage (range: 0.5–2 mg). The T1 neuropsychological
testing was administered in the afternoon (around 4 p.m.).
To avoid the potential bias of learning/practice effect at T1,
neuropsychological tests that have been demonstrated not to be
influenced by learning, and/or parallel/alternate forms of the test
previously administered at T0, were used (Carlesimo et al., 1996;
Amodio et al., 2008; Casarotti et al., 2014; Goretti et al., 2014;
Zucchella et al., 2018a).
Verbal Memory
Verbal memory was assessed with the Italian versions of the
Digit Span Forward Test (DSFT) and the Rey Auditory Verbal
Learning Test (RAVLT), which is divided into immediate recall
(IR) and delayed recall (DR) tests. DSFT measures short-
term memory. Subjects are asked to repeat progressively longer
digit series starting from three up to the longest series they
can remember (Monaco et al., 2013). RAVLT explores verbal
learning and memory. Subjects are asked to repeat all words
they can remember from a list of 15 unrelated words the
examiner read aloud previously (IR test, five trials) and to recall
the previously presented words after 10-min delay (DR test)
(Carlesimo et al., 1996).
Visuospatial Memory
Visuospatial memory was assessed with the Rey-Osterrieth
Complex Figure Test (ROCF), where subjects are asked to copy
a complex bidimensional figure (IR) and then redraw it after a
10-min delay (DR) (Caffarra et al., 2002).
Working Memory
Working memory was assessed with the Digit Span Backward
Test (DSBT), which is the same as DSFT, but subjects are
asked to recall the digit series in reverse of the presented order
(Monaco et al., 2013).
Attention
Attention was assessed with the Trail Making Test Part A (TMT-
A) and the Symbol Digit Modalities Test (SDMT) (Amodio et al.,
2008; Goretti et al., 2014). TMT-A explores selective attention
and visuospatial exploration, by asking the subject to draw lines
sequentially connecting 25 encircled numbers. The time required
to complete the task and the number of errors are recorded.
SDMT is a measure of psychomotor speed. Subjects are required
to transcribe symbols to numbers in the shortest time possible.
The SDMT score is the number of correct answers in 90 s.
Executive Functions
Executive functions were evaluated with the Trail Making Test
Part B (TMT-B), the Stroop test and the Phonemic Verbal
Fluency Test (PVFT). TMT-B is similar to TMT-A, except
that the task evaluates mental flexibility and task switching
by asking the subjects to alternate between numbers and
letters (Amodio et al., 2008). The Stroop test is a measure
of inhibitory control. The subjects are asked to read color-
related words printed in black type, name the color in which
words are typed, and read color-related words typed in a
different color (i.e., the word “blue” written in red type). The
time to complete the task and the number of errors were
recorded (Brugnolo et al., 2016). The PVFT measures lexical
access, mental flexibility and abstract thinking by asking the
subjects to generate as many words beginning with three
test letters as possible in a given time (60 s for letter).
The PVFT score is the total number of words reported
(Carlesimo et al., 1996).
Depression and Anxiety
Depression was explored with the Beck Depression Inventory II
(BDI-II), a 21-item self-administered questionnaire (score 0–3
for each item, cut-off for moderate to severe depression 28) to
measure the severity of depressive symptoms during the previous
2 weeks (Federico et al., 2017). The internal consistency and test-
retest reliability for the Italian version range from 0.76 to 0.87
(Sica and Ghisi, 2007).
Anxiety was assessed with the State Trait Anxiety Inventory
form Y (STAI-Y) that is composed of two 20-item self-applied
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questionnaires to measure state and trait anxiety. Each item
is scored on a 1–4 Likert-type format; the cut-off for mild
anxiety is 40 (Federico et al., 2017). The test-retest reliability
for the STAI-Y state scale and the trait scale is 0.49 and
0.82, respectively (Pedrabissi and Santiniello, 1989). The internal
coherence (Cronbach’s alpha) varies from 0.91 to 0.95 for
the state scale and from 0.85 to 0.90 for the trait scale
(Pedrabissi and Santiniello, 1989).
Flumazenil Infusion
All patients underwent slow subcutaneous infusion of flumazenil
(40.5 µg/hour for 24 h/day for 7 days) through an elastomeric
pump (Faccini et al., 2016). They also received oral clonazepam
at decreasing dosage from 5–6 mg on the first day to 0.5–2 mg
on last day of flumazenil infusion, and prophylactic antiepileptic
treatment to reduce the risk of seizures. The antiepileptic
treatment was administered during the whole detoxification
period (Faccini et al., 2016; Tamburin et al., 2017a). The mean
dosage of levetiracetam (N = 27 patients) was 979.2 ± 70.6 mg,
and the mean dosage of valproate (N = 23 patients) was
1025.0 ± 111.8 mg.
Statistical Analysis
Data were analyzed with SPSS version 21.0 (SPSS, Chicago,
IL, United States). Fisher’s exact test was applied to categorical
variables. For continuous variables, normality of distribution was
tested with the Shapiro-Wilks test. Differences between patients
and controls for baseline variables and neuropsychological
scores at T0 were analyzed with Student’s t-test in case of
normal distribution, or the non-parametric Mann-Whitney U
test when the distribution was not normal. The potential
confounder effect of sex, age, and education was explored
by comparing patients (T0) vs. controls with a multivariate
generalized linear model with sex, age and education as
covariates (Federico et al., 2017). The effect of clinical
variables (BDI-II; STAI-Y state and trait; DDDE; high-dose
BZD abuse duration; prophylactic antiepileptic treatment) on
neuropsychological tests was explored by first entering them
into univariate analysis (continuous variables: non-parametric
Spearman’s rho correlation coefficient; categorical variables:
Kruskal-Wallis H rank test), then variables that were significant
in the univariate model were entered as covariates into linear
regression multivariate models with neuropsychological scores
as dependent outcomes. Within-subject T1–T0 differences in
neuropsychological scores were explored with paired t-test
when the distribution was normal, or the non-parametric
Wilcoxon signed-rank order test for non-normal distributions.
Neuropsychological scores were reported as Z-scores according
to the formula: Z-score = (measured value – mean value
according to age and education)/standard deviation according
to age and/or education. Negative and positive values indicated
worse and better performance than the normal population,
respectively. Z-scores was computed for scores with normal
distribution in the normative sample, i.e., DSFT and TMT-A/B
time (sec), DSBT, ROCF-DR (Carlesimo et al., 2002; Mondini
et al., 2011; Monaco et al., 2013). P < 0.05 (two-tailed) was the
significance threshold for all the tests.
RESULTS
The abused BZD was lormetazepam in 34 patients (68%),
zolpidem in 7 (14%), alprazolam in 4 (8%), lorazepam in 2
(4%), triazolam in 1 (2%) and clonazepam in 1 (2%), while
1 patient abused of lormetazepam and zolpidem (2%). The
DDDE was 436.7 ± 397.3 mg (median 250, interquartile range,
IQR 225–600). The duration of high-dose BZD abuse was
119.7 ± 96.7 months (median 96, IQR 42–180).
The BDI-II score at T0 was 29.7 ± 8.9/63 (median 31, IQR 24–
35.5), which indicated moderate-to-severe depression. At T0, the
STAI-Y state anxiety score was 39.6 ± 5.8/80 (median 39, IQR
34–44), and the trait anxiety score was 44.0 ± 9.4/80 (median 44,
IQR 39–52), which indicated mild anxiety.
Prophylactic antiepileptic treatment during flumazenil
infusion (Tamburin et al., 2017a) was levetiracetam in 26
patients, valproate in 21, lamotrigine in 2 and topiramate in 1.
There were neither seizures nor adverse effects related to the
detoxification with slow subcutaneous infusion of flumazenil.
There were no drop-outs.
At T0, the patients group scored significantly worse
than healthy controls group in all the neuropsychological
tests (Table 2).
Multivariate linear regression model showed a significant
positive effect (i.e., the higher the anxiety score, the better the
performance) of STAI-Y state score on RAVLT-IR (β = 0.58;
95% confidence interval, CI: 0.13, 1.02; p = 0.012) and RAVLT-
DR (β = 0.14; 95% CI: 0.01, 0.26; p = 0.03). BDI-II score
had a significant negative effect on DSFT (β = −0.03; 95% CI:
−0.06, −0.01; p = 0.023). High-dose BZD abuse duration had a
significant negative effect on SDMT (β = −0.04; 95% CI: −0.06,
−0.01; p = 0.004).
T1–T0 comparison showed that the patient group significantly
improved performances in all neuropsychological tests after the
end of detoxification period (Table 3). Z-scores at T0 and T1 are
reported in Figure 2.
DISCUSSION
The new finding of this study is that cognitive abnormalities
were significantly ameliorated after BZD detoxification by slow
subcutaneous infusion of flumazenil. Our data also confirmed
that all neuropsychological domains were significantly impaired
by high-dose BZD abuse (Federico et al., 2017).
The cognitive changes we found are in keeping with
previous studies and a meta-analysis showing moderate-to-
large abnormalities in all cognitive domains to long-term BZD
use (Barker et al., 2004a; Boeuf-Cazou et al., 2011; Puustinen
et al., 2014; Helmes and Østbye, 2015; Fond et al., 2018). In
particular, an updated meta-analysis found statistically significant
impairment of many neuropsychological domains (i.e., working
memory, divided attention, processing speed, visuoconstruction,
recent memory and expressive language) to long-term BZD use
(Crowe and Stranks, 2018).
Some pharmacological lines of reasoning may explain the
neuropsychological abnormalities we found. BZDs act at an
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TABLE 2 | Neuropsychological measures in high-dose BZD abusers (T0) and healthy controls.
Neuropsychological test High-dose BZD abusers (N = 50)a Healthy controls (N = 50)a p value
Verbal memory
DSFT 5.6 ± 0.8, 6, 5 − 6 6.2 ± 0.5, 6, 6 − 6.5 0.00028
RAVLT-IR 37.6 ± 9.8, 39.5, 30.5 − 44.5 50.5 ± 5.0, 51, 4.75 − 55 <0.0001
RAVLT-DR 7.6 ± 2.7, 8, 5 − 9 13.8 ± 1.5, 14, 13 − 15 <0.0001
Visuospatial memory
ROCF-IR 31.2 ± 6.5, 34, 29 − 36 35.8 ± 0.6, 36, 36 − 36 <0.0001
ROCF-DR 11.1 ± 6.6, 11.5, 5 − 15.75 26.2 ± 3.3, 27, 24 − 29 <0.0001
Working memory
DSBT 3.2 ± 1.0, 3, 2 − 4 4.7 ± 0.6, 5, 4 − 5 <0.0001
Attention
TMT-A (time, s) 52.7 ± 23.3, 48, 37 − 66 23.1 ± 4.9, 23.5, 19 − 27 <0.0001
TMT-A (errors, N) 0.6 ± 1.0, 0, 0 − 1 −b <0.0001
SDMT 28.7 ± 8.5, 29, 20.5 − 33 44.9 ± 9.2, 48, 38 − 53 <0.0001
Executive functions
TMT-B (time, s) 131.5 ± 57.8, 115, 78.5 − 179 47.5 ± 9.2, 47, 41.75 − 52.25 <0.0001
TMT-B (errors, N) 2.8 ± 2.3, 3, 0 − 5 −b <0.0001
Stroop test (time, s) 32.5 ± 9.2, 31, 28.5 − 36 19.2 ± 3.6, 19.5, 16.5 − 22.125 <0.0001
Stroop test (errors, N) 1.9 ± 2.2, 1, 0 − 4 0.02 ± 0.1, 0, 0 − 0 <0.0001
PVFT 29.7 ± 11.1, 29.5, 21 − 35.5 42.5 ± 5.3, 43, 39 − 46 <0.0001
DR, delayed recall; DSBT, Digit Span Backward Test; DSFT, Digit Span Forward Test; BZD, benzodiazepine; IR, immediate recall; PVFT, Phonemic Verbal Fluency
Test; RAVLT, Rey Auditory Verbal Learning Test; ROCF, Rey-Osterrieth Complex Figure Test; SDMT, Symbol Digit Modalities Test; T0, 28–30 days before admission for
detoxification with flumazenil slow subcutaneous infusion; TMT-A/B, Trail Making Test Part A/B. aData reported as mean ± S.D., median, interquartile range. bNone of the
healthy controls made any error in this test.
TABLE 3 | Comparison of neuropsychological measures in high-dose BZD abusers at T0 and T1.
Neuropsychological test T0a T1a t/Z valueb p value
Verbal memory
DSFT 5.6 ± 0.8, 6, 5 − 6 5.9 ± 0.8, 6, 5 − 7 Z = −2.97 0.003
RAVLT-IR 37.6 ± 9.8, 39.5, 30.5 − 44.5 42.7 ± 8.1, 43, 35 − 48 Z = −5.03 <0.0001
RAVLT-DR 7.6 ± 2.7, 8, 5 − 9 9.2 ± 2.8, 9, 7 − 11 Z = −5.21 <0.0001
Visuospatial memory
ROCF-IR 31.2 ± 6.5, 34, 29 − 36 32.7 ± 5.5, 36, 32 − 36 Z = −3.47 0.001
ROCF-DR 11.1 ± 6.6, 11.5, 5 − −15.8 13.1 ± 5.5, 12.5, 9.5 − 16 Z = −4.15 <0.0001
Working memory
DSBT 3.2 ± 1.0, 3, 2 − 4 3.6 ± 0.9, 4, 3 − 4 Z=−4.20 <0.0001
Attention
TMT-A (time, s) 52.7 ± 23.3, 48, 37 − 66 42.7 ± 14.3, 40.5, 30 − 51 Z=−5.03 <0.0001
TMT-A (errors, N) 0.6 ± 1.0, 0, 0 − 1 0.06 ± 0.3, 0, 0 − 0 Z = −3.60 <0.0001
SDMTc 28.7 ± 8.5 35.6 ± 7.0 t = −11.76 <0.0001
Executive functions
TMT-B (time, s) 131.5 ± 57.8, 115, 78.5 − 179 92.5 ± 35.4, 85.5, 67 − 112 Z = −5.68 <0.0001
TMT-B (errors, N) 2.8 ± 2.3, 3, 0 − −5 0.6 ± 1.4, 0, 0 − −1 Z = −4.68 <0.0001
Stroop test (time, s) 32.5 ± 9.2, 31, 28.5 − 36 26.7 ± 5.7, 25 − 31 Z = −5.24 <0.0001
Stroop test (errors, N) 1.9 ± 2.2, 1, 0 − 4 0.3 ± 0.7, 0, 0 − 0 Z = −4.82 <0.0001
PVFTc 29.7 ± 11.1 39.5 ± 9.6 t = −14.55 <0.0001
DR: delayed recall; DSBT: Digit Span Backward Test; DSFT: Digit Span Forward Test; BZD: benzodiazepine; IR: immediate recall; PVFT: Phonemic Verbal Fluency
Test; RAVLT: Rey Auditory Verbal Learning Test; ROCF: Rey-Osterrieth Complex Figure Test; SDMT: Symbol Digit Modalities Test; T0: 28–30 days before admission for
detoxification with flumazenil slow subcutaneous infusion. T1: at the end of flumazenil slow subcutaneous infusion, 7 days after admission; TMT-A/B: Trail Making Test
Part A/B. aData reported as mean ± S.D., median, interquartile range (mean ± S.D. for variables with normal distribution). bPaired t-test in case of normal distribution, or
Wilcoxon signed-rank order test (Z-value) for non-normal distributions. cVariables with normal distribution.
allosteric modulator site on the GABA-A receptor channel
complex, which is composed by 5 (usually 2 α, 2 β, 1 γ)
subunits surrounding a chloride pore and modulate cerebral
functions through α subunits, which show distinct expression
patterns in the brain (Tan et al., 2011). α1 is responsible
for sedation, anterograde amnesia, anticonvulsant effects and
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FIGURE 2 | Neuropsychological measures at T0 (black boxes) and T1 (white boxes) represented as Z-scores. Negative values indicating worse performance and
positive values indicating better performance than the average value of the normal population.
BZD dependence, α2 and α3 are associated with anxiolytic
and myorelaxant actions, and α5 is related to cognition,
learning and memory (Tan et al., 2011; Möhler, 2015). The
GABA-A receptor channel complex has been suggested to
contribute to the cognitive dysfunction in traumatic brain injury
(Sun and Feng, 2014).
Zolpidem, which displays α1 selective affinity, but almost
no effect on the α5 subunit, may produce more memory and
cognitive impairment than triazolam, an agonist of all α subunits
(Roehrs et al., 1994), suggesting that α1 plays a major role in
the amnestic effect of BZDs. We hypothesize that the severe
memory dysfunction we found at T0 in patients may be ascribed
to the larger number of them abusing lormetazepam and/or
zolpidem, which have a remarkable selectivity for the α1 subunit
(Crestani et al., 2000).
Partial α5 knockdown in the mice hippocampus improves
trace fear conditioning (Crestani et al., 2002), appetitive
conditioning and novel object recognition (Yee et al., 2004), and
complete α5 deficit causes improved spatial performance and
trace fear memory (Martin et al., 2010). The α5 subunit is located
extrasynaptically in the hippocampal pyramidal cell dendrites,
where it mediates tonic inhibition (Möhler, 2015). Excessive
activation of α5 GABA-A receptors by high-dose BZDs may
inhibit glutamate-mediated excitatory transmission and worsen
cognitive performance in BZD abusers.
Long-term BZD administration is associated with changes in
GABAergic and dopaminergic neurons in the ventral tegmental
area and other brain regions (Tan et al., 2011). Animal models
indicate that prolonged α1 stimulation induces a shift in the
expression of α isoforms, causing reduction of α1, α2, increase
of α3, α4 and α6, and reduction or increase in α5 subunits (Tan
et al., 2011). α4 and α6 subunits are nearly insensitive to BZDs,
and the changes in the composition of the GABA-A receptor
result in BZD-receptor decoupling, a compensatory mechanism
that contributes to BZD tolerance (Cheng et al., 2018). While
tolerance to sedative and anticonvulsant effects builds quickly in
humans and animal models, cognitive effects of BZDs seem to
lack tolerance (Cheng et al., 2018).
The anticholinergic activity of BZDs might contribute to
cognitive dysfunction, in particular in persons aged 55 years
or older (Coupland et al., 2019), or with concomitant
neurological disorders (Forgacs and Bodis-Wollner, 2004), but
this mechanism seems unlikely in our patients because of their
young age and the absence of neurological comorbidities that
rule out the hypothesis of subclinical brain cholinergic damage
(Risacher et al., 2016).
Benzodiazepine dosage, expressed as DDDE, did not have any
effect on cognition in our sample, probably because the high dose
resulted in a ceiling effect (Federico et al., 2017). Abuse duration
had a significant negative effect on psychomotor speed assessed
by the SDMT, suggesting a possible neuroplasticity effect causing
worse performance with longer high-dose BZD intake (Möhler,
2015; Ruparelia et al., 2012).
Different hypotheses can explain the improvement of the
neuropsychological outcomes at T1. In keeping with a meta-
analysis reporting that long-term BZD users show partial
cognitive recovery after withdrawal (Barker et al., 2004b),
discontinuation of high-dose BZD and its replacement
by low-dose clonazepam is the most likely reason for
neuropsychological improvement.
In accordance with experimental evidence of reversal of
BZD-induced cognitive impairment by flumazenil (Wesensten
et al., 1995), flumazenil infusion could have ameliorated
cognition through negative allosteric modulation of α1 and α5
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GABA-A receptor function. Pharmacological blockade of α5
subunit function has been suggested to enhance learning and
memory (Ballard et al., 2009) in animal models of Down’s
syndrome that is supposed to be characterized by reduced long-
term potentiation and excessive long-term inhibition in the
hippocampus (Ruparelia et al., 2012). A short-term course of
flumazenil was demonstrated to restore long-term object memory
in a mouse model of Down’s syndrome (Colas et al., 2017).
Flumazenil may have contributed to reverse α isoform changes
associated with prolonged BZD exposure through α6 agonist
effect (Tamburin et al., 2017a). This hypothesis is in keeping with
animal models of autism spectrum disorders, where rebalance of
α2, α3, and α5 GABA-A receptor activity has been reported to
improve cognitive and behavioral disturbances (Han et al., 2012;
Möhler, 2015).
We excluded patients with dementia or other
neurodegenerative conditions, major psychiatric diseases,
and concurrent alcohol or other substance use disorder, which
may contribute to cognitive impairment in patients taking BZDs
and represented a bias to demonstrate a direct link between
BZD intake and neuropsychological deficits in previous studies
(Verdoux et al., 2005; Billioti de Gage et al., 2014).
Depression and anxiety, which may influence cognition
(Krysta et al., 2015) were not ruled out in our sample, because
they are frequently comorbid in high-dose BZD abusers. The
BDI score was, on average, moderate-to-severe, it was found to
have a significant negative effect on DSFT only, but no influence
on other neuropsychological outcomes. Anxiety was mild on
average, and had significantly positive effect (i.e., the higher the
anxiety score, the better the performance) on RAVLT scores.
Taken together, these results indicate a potential mild bias effect
of psychiatric comorbidity on verbal memory test scores.
The main limitation of this study is the absence of a control
group not undergoing BZD detoxification (e.g., people taking
clonazepam only at decreasing dosage), but such a design
would have raised ethical issues. In addition, the presence
of another group of BZD users not requiring flumazenil
treatment would have been an important control. Another
limitation stems from the relatively short time between T0
and T1 that might have resulted in a learning effect. To
reduce this potential source of bias, we chose neuropsychological
tests that have been demonstrated not to be influenced by
learning, and/or we used parallel/alternate forms (Zucchella
et al., 2018a). Indeed, cognitive re-testing of healthy controls
at T1 would have strengthened our results. Furthermore,
the prophylactic antiepileptic treatment may have influenced
cognitive outcome at T1, but its effect was eventually to worsen
cognition, and this treatment was necessary to reduce the risk of
seizures. The impact of coexisting psychiatric comorbidities (i.e.,
depression, anxiety disorders) on neuropsychological measures,
despite being probably less severe than that of high-dose
BZD abuse, could not be completely ruled out. Finally, we
did not include further follow-ups at longer times from the
end of flumazenil infusion and this point is a limitation
of the study. Future studies should assess the long-term
outcomes to slow subcutaneous flumazenil infusion. Also,
functional neuroimaging or evoked related potential data
would have offered evidence on underlying brain changes
related to BDZ intake.
CONCLUSION
In conclusion, we found detoxification to significantly ameliorate
the severe and multidomain neuropsychological dysfunction
in high-dose BZD abuse. The standard treatment for BZD
detoxification is slow tapering that may last months in case of
high-dose abuse (Soyka, 2017). Our results strengthen the clinical
significance of slow subcutaneous flumazenil infusion for high-
dose BZD detoxification, because cognitive impairment is one of
the main reasons to seek medical assistance (Federico et al., 2017)
and results in poorer quality of life (Tamburin et al., 2017b) in this
substance use disorder, thus requiring rapid treatment.
Even in the presence of the abovementioned limitations, these
findings could be of interest in that they suggest that 7 days of
slow subcutaneous infusion of flumazenil may, at least partially,
improve BZD-related cognitive deficits. Further randomized
controlled studies with long-term follow-up are needed before
flumazenil slow cutaneous infusion can be considered as a
standard treatment for high-dose benzodiazepine abusers.
The present data may also indicate future research lines.
Animal studies indicate that chronic administration of
flumazenil increases the life span and protects rats from cognitive
worsening during aging, suggesting that age-related excessive
BDZ/GABAergic activity may promote neurodegeneration
(Colas et al., 2017). Whether flumazenil might have a therapeutic
role in age-related neurodegenerative conditions leading to
dementia in humans is an interesting research topic, given the
absence of disease-modifying treatments (Zucchella et al., 2018b)
that may be used early in the course of the disease to block or
delay neurodegeneration (Emery, 2011).
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